FDA Approves the Launch of Clinical Trials to Assess IPF Candidate BBT-877
Bridge Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) recently approved the company’s Investigational New Drug (IND) application for BBT-877. The company now has permission to start human clinical trials with this potential therapy for idiopathic pulmonary fibrosis (IPF). The IND application was submitted in November 2018.